BFA
EIGR

BlackRock Fund Advisors’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

BlackRock Fund Advisors’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$1.53M Buy
4,367
+671
+18% +$246K ﹤0.01% 3197
2016
Q3 		$1.49M Buy
3,696
+687
+23% +$351K ﹤0.01% 3202
2016
Q2 		$1.79M Buy
3,009
+2,896
+2,563% +$1.76M ﹤0.01% 3210
2016
Q1 		$57K Sell
113
-7
-6% -$3.48K ﹤0.01% 3776
2015
Q4 		$79K Sell
120
-760
-86% -$430K ﹤0.01% 3789
2015
Q3 		$416K Buy
880
+147
+20% +$78K ﹤0.01% 3263
2015
Q2 		$416K Buy
733
+39
+6% +$108K ﹤0.01% 3258
2015
Q1 		$5.92M Buy
694
+46
+7% +$402K ﹤0.01% 2749
2014
Q4 		$5.7M Buy
648
+608
+1,520% +$3.53M ﹤0.01% 2801
2014
Q3 		$187K Sell
40
-3
-7% -$15.8K ﹤0.01% 3496
2014
Q2 		$307K Sell
43
-342
-89% -$1.71M ﹤0.01% 3333
2014
Q1 		$2.06M Buy
+385
New +$1.82M ﹤0.01% 3136

Other funds holding EIGR

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock Fund Advisors's EIGR Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Eiger BioPharmaceuticals, Inc. (EIGR) stake by 18% in Q4 2016, buying an estimated $246K and bringing the position to 4,367 shares worth $1.53M. The position accounts for ﹤0.01% of the portfolio, ranked #3197.

BlackRock Fund Advisors first reported a position in EIGR in Q1 2014 and has held it in 12 quarters since. The position peaked at $5.92M in Q1 2015. 51 funds tracked by Wall St. Rank hold EIGR as of Q4 2016.

  • BlackRock Fund Advisors held 4,367 shares of Eiger BioPharmaceuticals, Inc. worth $1.53M as of Q4 2016.
  • BlackRock Fund Advisors bought 671 Eiger BioPharmaceuticals, Inc. shares in Q4 2016, an estimated $246K.
  • Eiger BioPharmaceuticals, Inc. made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #3197 holding.
  • BlackRock Fund Advisors first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2014 and has held it in 12 quarters since.
  • BlackRock Fund Advisors's Eiger BioPharmaceuticals, Inc. position peaked at $5.92M in Q1 2015.
  • 51 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.